脑脊液中内源性大麻素大麻酰胺水平在未经治疗的 1 型发作性睡病患者中降低：一项初步研究。
CSF Levels of the Endocannabinoid Anandamide are Reduced in Patients with Untreated Narcolepsy Type 1: A Pilot Study.
机构信息
IRCCS Neuromed Sleep Medicine Center, Via Atinense, 18 Pozzilli (IS), Italy.
Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy.
出版信息
CNS Neurol Disord Drug Targets. 2020;19(2):142-147. doi: 10.2174/1871527319666200309115602.
BACKGROUND
Endocannabinoids (ECs) modulate both excitatory and inhibitory components in the CNS. There is a growing body of evidence that shows ECs influence both hypothalamic orexinergic and histaminergic neurons involved in narcolepsy physiopathology. Therefore, ECs may influence sleep and sleep-wake cycle.
OBJECTIVE
To evaluate EC levels in the CSF of untreated narcoleptic patients to test whether ECs are dysregulated in Narcolepsy Type 1 (NT1) and Type 2 (NT2).
METHODS
We compared CSF Anandamide (AEA), 2-Arachidonoylglycerol (2-AG) and orexin in narcoleptic drug-naïve patients and in a sample of healthy subjects.
RESULTS
We compared NT1 (n=6), NT2 (n=6), and healthy controls (n=6). We found significantly reduced AEA levels in NT1 patients compared to both NT2 and controls. No differences were found between AEA levels in NT2 versus controls and between 2-AG levels in all groups, although a trend toward a decrease in NT1 was evident. Finally, the CSF AEA level was related to CSF orexin levels in all subjects.
CONCLUSION
We demonstrated that the EC system is dysregulated in NT1.
背景
内源性大麻素 (ECs) 调节中枢神经系统中的兴奋性和抑制性成分。越来越多的证据表明，ECs 影响参与发作性睡病病理生理学的下丘脑食欲素能和组胺能神经元。因此，ECs 可能会影响睡眠和睡眠-觉醒周期。
目的
评估未经治疗的发作性睡病患者脑脊液中的 EC 水平，以测试 ECs 是否在 1 型发作性睡病 (NT1) 和 2 型发作性睡病 (NT2) 中失调。
方法
我们比较了发作性睡病药物未治疗的患者和健康受试者的脑脊液中 Anandamide (AEA)、2-Arachidonoylglycerol (2-AG) 和食欲素。
结果
我们比较了 NT1（n=6）、NT2（n=6）和健康对照组（n=6）。我们发现 NT1 患者的 AEA 水平明显低于 NT2 患者和对照组。NT2 患者与对照组之间的 AEA 水平以及所有组之间的 2-AG 水平没有差异，尽管 NT1 有降低的趋势。最后，所有受试者的脑脊液 AEA 水平与脑脊液食欲素水平相关。
结论
我们证明了 EC 系统在 NT1 中失调。
Zotero 插件